Redox signaling-governed drug-tolerant persister cancer cell:a key spark of treatment failure  

作　　者：Liwu Fu Zhe-Sheng Chen 

机构地区：[1]State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangdong Esophageal Cancer Institute,Cancer Center,Sun Yat-Sen University,Guangzhou 510060,China [2]Department of Pharmaceutical Sciences,College of Pharmacy and Health Sciences,St.John’s University,Queens,NY 11439,USA [3]Institute for Biotechnology,St.John’s University,Queens,NY 11439,USA

出　　处：《Signal Transduction and Targeted Therapy》2022年第4期955-957,共3页信号转导与靶向治疗（英文）

摘　　要：In a recent study published in EMBO Molecular medicine,Zhang et al.provided a novel insight regarding better knowledge of the drug resistant contribution of drug-tolerant persister(DTP)state in tumor evolution,especially in terms of mechanistic insights into redox regulation involved,unambiguously establishing a novel therapeutic strategy of treating multi-drug-resistant(MDR)cancer cells and preventing tumor recurrence by disequilibrating Niemann–Pick C1-like 1(NPC1L1)-mediated redox homeostasis.

关 键 词：cancer HOMEOSTASIS INSIGHT 

分 类 号：R73[医药卫生—肿瘤] R91[医药卫生—临床医学]